Our findings have important implications for the subsequent counseling and management of p.Ser36Tyr carriers, since they have an increased risk over the general population for developing breast/ovarian cancer, although this risk is lower than that observed for pathogenic BRCA1 mutations. The gene discussed is BRCA1; the disease is ovarian cancer.